item management s discussion and analysis of financial condition and results of operations management s discussion and analysis the following discussion contains forward looking statements which involve risks and uncertainties 
the company s actual results may differ significantly from the results discussed in the forward looking statements 
factors that might cause such a difference include  but are not limited to  those discussed under liquidity and capital resources 
results of operations compared to contract revenues during were  compared to  in the contract revenue was realized by the company under a research agreement with biomet  inc biomet for the development of orthopedic implants using the company s proprietary dense fibrillar collagen 
the company and biomet have mutually agreed to replace the research agreement with a supply arrangement under which the company will sell collagen to biomet 
interest income in was  compared to  in research and development expenses increased to  from  in the increase was primarily due to the company s regulatory filing and preparation for commercialization of graftskin tm and related increases in resources in clinical research  cryobiology  quality assurance  and process scale up 
the increase was also due in part to the company establishing research collaborations with leading academic institutions  including harvard medical school and hebrew university  to further enhance its product portfolio 
general and administrative expenses increased to  in from  in  primarily due to higher legal  consulting and other professional services resulting mainly from the public offering  the collaborative agreement with sandoz  and supporting the activity in research and development 
the company s net loss for was  or per share  as compared with a net loss for of  or 
per share 
compared to contract revenues during were  compared to  in contract revenues in were realized by the company under an agreement with biomet for the development of orthopedic implants using the company s proprietary dense fibrillar collagen 
contract revenues in were realized under agreements with eli lilly and company lilly relating to the development of the company s graftartery product and with biomet 
the company s collaboration with lilly ended in july no sale of product occurred in  as compared to  in this was due to the company s discontinuance of the manufacturing and selling of its testskin products 
interest income in was  compared to  in the decrease in resulted from less cash available for investment 
research and development expenses increased to  from  in the increase was primarily due to higher employment related costs resulting from staff additions and data management and statistical services related to human clinical trials for graftskin tm 
general and administrative expenses decreased to  in from  in  primarily as a result of lower outside services rendered to the company 
the company s net loss for was  or 
per share  as compared with a net loss for of  or 
per share 
liquidity and capital resources from inception  the company has financed its operations substantially through private and public placements of equity securities  as well as receipt of contract revenues  interest income from investments and  to a lesser extent  sale of products 
at december  and  respectively  the company had cash  cash equivalents and investments in the aggregate of  and  the increase was primarily due to the completion of a public offering in july in which the company received net proceeds of  from the sale of  shares of common stock and  unit warrants 
in january  the company and sandoz ltd 
sandoz entered into an agreement that grants sandoz exclusive worldwide marketing rights to graftskin tm 
the company will supply sandoz s global requirements for the product and receive payment for each unit 
the company will also receive royalty revenues on all graftskin tm sales 
in addition  sandoz will provide the company with up to  in equity investments  milestone payments  and research support payments  including an initial  equity investment at per share and additional equity investments of  upon achievement of specified milestones 
subsequent to december   the company received proceeds from sandoz of  representing the first equity investment in the company and  representing the first contribution to the company s research and development costs for graftskin tm 
as a result of this initial equity investment  sandoz holds approximately of the outstanding shares of organogenesis 
the company will continue to utilize working capital in related to ongoing product research and development activities  conducting preclinical and clinical trials  enhancement of proprietary manufacturing technologies and expansion of business development  general and administrative resources 
these activities will require substantial additional financial resources before the company can expect to realize revenue from product sales 
while management believes that additional financing composed of equity investments and funding provided under collaborative agreements will be available to fund future operations  and are being pursued  there can be no assurances that additional funds will be available when required on terms acceptable to the company 
based upon its current plans  the company believes that the future equity and research contributions from sandoz  together with existing working capital  will be sufficient to fund its operations at least through the second quarter of however  the company s capital requirements may vary depending on numerous factors  including progress of the company s research and development programs  time required to obtain regulatory approvals  resources the company devotes to self funded projects  proprietary manufacturing methods and advanced technologies  and the demand for the company s products  if and when  approved 
the company is subject to risks common to companies in the biotechnology industry including  but not limited to  development by the company or its competitors of new technological innovations  risks of failure of clinical trials  dependence on key personnel  protection of proprietary technology  compliance with united states food and drug administration regulations and ability to transition from pilot scale manufacturing to large scale production of products 
in october  the financial accounting standards board issued statement of financial accounting standards no 
 accounting for stock based compensation sfas  which is effective for transactions entered into in fiscal years that begin after december  sfas establishes a fair value based method of accounting for stock based compensation plans 
the company plans to adopt the disclosure method in the company has not determined the effect on a proforma basis to net income and earnings per share  of applying fair value accounting rules to grants of stock based awards in 
